A new study , conducted in Europe , found the medicine worked just as well as an earlier disputed study , sponsored by ImClone Systems , said it did .
Doctors concluded Erbitux , the cancer drug that enmeshed ImClone Systems in an insider trading scandal , worked just as well as an earlier company-sponsored study said it did .
Recall proponents say they have turned in nearly twice the number of necessary signatures .